# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001493152-19-013333
Filing Date
2019-08-26
Accepted
2019-08-26 06:09:48
Documents
7
Effectiveness Date
2019-08-26

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 |  | formdefa14a.htm | DEFA14A | 32530
2 |  | proxy_001.jpg | GRAPHIC | 258838
3 |  | proxy_002.jpg | GRAPHIC | 330739
4 |  | proxy_003.jpg | GRAPHIC | 124285
5 |  | proxy_004.jpg | GRAPHIC | 82048
6 |  | proxy_005.jpg | GRAPHIC | 339155
7 |  | proxy_006.jpg | GRAPHIC | 277015
| Complete submission text file | 0001493152-19-013333.txt |  | 1977672

Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Filer) CIK: 0001022899 (see all company filings)

EIN.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-51353 | Film No.: 191050451
SIC: 7389 Services-Business Services, NEC